Veraxa Biotech Holding AG (VRXA) reported that VERAXA Biotech AG and Secarna Pharmaceuticals achieved an initial research milestone in their antibody oligonucleotide conjugate (AOC) alliance targeting autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate created using both companies’ technologies showed greater potency than the equivalent unconjugated oligonucleotide, suggesting enhanced therapeutic potential for targeted delivery. Both companies are now discussing the next steps in the collaboration. VERAXA positions this work as an extension of its antibody-based platforms beyond oncology, while Secarna contributes its AI-enabled OligoCreator platform for oligonucleotide discovery and delivery.
Veraxa Biotech Holding AG (VRXA) filed an initial statement of beneficial ownership (Form 3) for reporting person Carl von Halem, who serves as Interim CFO. The filing does not report any equity transactions or holdings, and no Rule 10b5-1 trading plan is indicated.
AQR Capital Management, LLC, together with AQR Capital Management Holdings, LLC and AQR Arbitrage, LLC, reports its beneficial ownership in Veraxa Biotech Holding AG Ordinary Shares on an amended basis. The group reports beneficial ownership of 658,138 Ordinary Shares, including warrants representing 658,138 Ordinary Shares, par value CHF 100/11,325 per share.
This position represents 0.46% of Veraxa’s outstanding Ordinary Shares. The AQR entities report no sole voting or dispositive power, and shared voting and shared dispositive power over all 658,138 shares. The filing confirms that the AQR group now holds 5% or less of this class of securities.
Veraxa Biotech AG is registering up to 19,436,739 Ordinary Shares issuable upon exercise of outstanding Public and Private Warrants at $11.50 per share. A further 120,295,385 Ordinary Shares and 6,786,739 Private Warrants may be resold from time to time by selling securityholders.
The company will receive no proceeds from these resales and only cash if Warrants are exercised, while holders may elect cashless exercise for Private Warrants. On August 7, 2026, Ordinary Shares closed at $1.99 and Warrants at $0.096, which the company believes makes warrant exercise unlikely while the price is below $11.50.
There were 141,407,813 Ordinary Shares outstanding as of the prospectus date. Veraxa is an oncology-focused biotech with no approved products, an accumulated deficit of CHF 66.6 million, and discloses it is an emerging growth company and a foreign private issuer using home-country Swiss corporate governance practices, which may offer shareholders fewer protections than U.S. domestic issuers.
Veraxa Biotech AG, a Swiss oncology-focused biotechnology company and emerging growth foreign private issuer, has filed a prospectus for the resale of up to 25,000,000 ordinary shares by Lincoln Park Capital Fund under a previously agreed purchase arrangement. These shares include 340,910 commitment shares already issued and up to 24,659,090 shares Veraxa may sell to Lincoln Park over a 24‑month term, tied to a total purchase commitment of up to $50,000,000. Veraxa will not receive proceeds from Lincoln Park’s resale of registered shares but may receive cash from future primary share sales to Lincoln Park under the Purchase Agreement, subject to a Beneficial Ownership Limitation of 4.99%, adjustable to 9.99%. Ordinary shares trade on Nasdaq Global Market under “VRXA” and warrants on Nasdaq Capital Market under “VRXAW.” Assuming all 25,000,000 shares are issued, ordinary shares outstanding would be 166,066,903. Veraxa emphasizes significant operating losses, need for substantial additional capital, clinical and regulatory risks for its oncology pipeline, and governance and disclosure differences arising from its Swiss domicile and foreign private issuer status.
VERAXA Biotech AG reported that it has strengthened its intellectual property around its BiTAC cancer therapy platforms. In the first half of 2026, the company filed initial patent applications for its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) technologies and related therapeutic programs, while previously granted auxiliary technology patents have cleared their opposition period.
VERAXA now has more than 50 granted owned or exclusively licensed patents in 14 countries, spread across 26 patent families, and expects recently filed applications, once granted, to protect its core technology suite through at least 2047. The BiTAC approach uses dual-component constructs and click-chemistry-based "click-to-release" payload activation to enhance tumor selectivity, safety, and manufacturability of next-generation antibody-based therapies.
Veraxa Biotech AG reported that its bispecific antibody drug conjugate program VXA-222, developed under a joint discovery alliance with OmniAb, Inc., has achieved a key technical milestone and is moving into its next collaboration phase after OmniAb concluded its discovery work.
VXA-222 applies an “AND-gate” logic, targeting two different antigens on solid tumors with a single molecule. The collaboration, established in May 2025, combines OmniAb’s transgenic antibody discovery technologies with Veraxa’s proprietary ADC linker and conjugation platform. Veraxa will now establish the bsADC lead candidate, conduct in vitro and in vivo validation, and holds exclusive rights to develop and commercialize products using OmniAb-derived antibodies, while OmniAb is entitled to a share of specified revenue. Veraxa highlights this as part of its broader strategy to advance next-generation antibody-based cancer therapeutics.
Veraxa Biotech AG reports that shareholders at the 24 July 2026 Extraordinary General Meeting approved all Board proposals, with more than 99.94% of votes cast on 102,102,301 voting shares, representing 72.20% of share capital. The amendments are intended to support long-term growth and strategic flexibility.
The Articles state share capital of CHF 1,248,634 + 50/453, divided into 141,407,813 registered shares with a par value of CHF 100/11,325 each. New authorizations add conditional share capital for equity-linked instruments, merger-related options, and employee and advisory plans, plus a capital band permitting issuance of up to 70,662,564 additional shares until 31 December 2030, in defined cases with excluded or limited subscription rights.
Governance changes include increasing the maximum Board size from five to seven and detailed rules on compensation approval, stock-based incentives and outside mandates. Veraxa also highlighted progress on its BiTAC T-cell engager program and named Carl von Halem interim CFO and Christoph Erkel, Ph.D. as Chief Scientific Officer.
Veraxa Biotech AG reported new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform for more precise, tumor-restricted cancer treatment. In studies, BiTAC-ADCs discriminated between breast cancer and healthy cells and showed efficient, dose-dependent killing of 3D tumor cell spheroids.
The platform uses two complementary antibody-delivered precursors to keep payloads inactive in circulation and activate them only inside tumor cells, aiming to reduce off-tumor toxicity. Veraxa will attend the BIO International Convention in San Diego from June 22-25, 2026 to discuss partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms.